Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.57

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $56.57.

AGIO has been the topic of several recent analyst reports. Scotiabank lifted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Finally, StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $33,000. GF Fund Management CO. LTD. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $39,000. Wingate Wealth Advisors Inc. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $53,000. Sterling Capital Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 1,587 shares during the last quarter. Finally, Quest Partners LLC grew its stake in shares of Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,283 shares during the last quarter.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $31.30 on Friday. The firm’s 50-day moving average is $33.38 and its 200-day moving average is $41.28. Agios Pharmaceuticals has a 1 year low of $27.14 and a 1 year high of $62.58. The company has a market cap of $1.79 billion, a P/E ratio of 2.76 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.